US › Healthcare

Ocular Therapeutix Inc (OCUL)

US · Healthcare · Biotechnology

$8.59+2.26%
Last close · 2026-08-04

Latest quarter · ended 2026-06-30

Revenue
$13.5M
Revenue YoY
+0.1%
Net profit
$-78.8M
Profit YoY
-16.1%
EPS
$-0.40
EPS estimate
$-0.31
Net margin
-584.5%

EPS came in at -0.40 against a street estimate of -0.31 — a miss of 29.0%.

Key statistics

Market cap
$1.79B
Forward P/E
0.0
P/B
3.07
Book value
$2.66
EPS (TTM)
$-1.44
52-week high
$16.44
52-week low
$6.23
50-day MA
$9.09
200-day MA
$10.10
Beta
0.88

Analyst view

Analysts rate Ocular Therapeutix Inc a strong buy (12 buy, 0 hold, 0 sell out of 12) with an average price target of $27.09.

Shareholding

Insiders
0.94%
Institutions
95.28%

Largest institutional holders

FundStake
FMR Inc14.91%
Deep Track Capital, LP8.99%
BlackRock Inc7.37%
venBio Select Advisor LLC5.62%
SUMMER ROAD LLC5.43%
VR Adviser, LLC4.73%
Vanguard Capital Management, LLC3.98%
T. Rowe Price Associates, Inc.2.69%

Recent filings & reports

DocumentDate
Quarterly report · Q2 20262026-08-03
Results announced · Q3 20262026-08-03
Board / officer change · Q2 20262026-06-12
Quarterly report · Q1 20262026-05-05
Results announced · Q2 20262026-05-05
Proxy statement · Q2 20262026-04-30
Reg FD disclosure · Q1 20262026-02-27
Annual report FY20252026-02-05

Readable in the app.

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Ocular Therapeutix Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.